22nd Century Group, Inc. is a plant biotechnology company focused on decreasing/increasing the level of nicotine in the tobacco plant through genetic engineering and breeding. The Company is focused on development of smoking cessation aid and owns and controls several patents. The company's products include X-22, a prescription smoking cessation aid, which is a tobacco-based botanical medical product for use as a smoking cessation therapy. 22nd Century Group, Inc. is based in Williamsville, New York.
Revenue (Most Recent Fiscal Year) | $24.38M |
Net Income (Most Recent Fiscal Year) | $-15.16M |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | 0.09 |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.57 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -55.67% |
Net Margin (Trailing 12 Months) | -57.62% |
Return on Equity (Trailing 12 Months) | -524.68% |
Return on Assets (Trailing 12 Months) | -57.04% |
Current Ratio (Most Recent Fiscal Quarter) | 0.68 |
Quick Ratio (Most Recent Fiscal Quarter) | 0.52 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
Inventory Turnover (Trailing 12 Months) | 10.76 |
Book Value per Share (Most Recent Fiscal Quarter) | $1.54 |
Earnings per Share (Most Recent Fiscal Quarter) | $-1.89 |
Earnings per Share (Most Recent Fiscal Year) | $-105.85 |
Diluted Earnings per Share (Trailing 12 Months) | -- |
Exchange | NASDAQ |
Sector | Consumer Defensive |
Industry | Tobacco |
Common Shares Outstanding | 2.36M |
Free Float | 2.35M |
Market Capitalization | $2.07M |
Average Volume (Last 20 Days) | 0.60M |
Beta (Past 60 Months) | 1.95 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 0.10% |
Percentage Held By Institutions (Latest 13F Reports) | 18.06% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |